Top Links

Articles Related to Bevacizumab

Compliance in the Duration of Administration of Anticancer Chemotherapy: Comparative Study of Two Different Administration Modalities (PVC versus IVAD)

Objective: To evaluate the compliance of chemotherapy administration duration by comparing the peripheral venous catheter (PVC) route with the implantable venous access device (IVAD).Keywords: Chemotherapy; Gravity perfusion; Peripheral venous; Implantable venous access deviceIntroduction Methods: This was a retrospective study that analyzed 566 cycles of chemotherapy administered by PVC at the Cancer Unit of Yalgado Ou├ędraogo University Hospital and 258 cycles administered by IVAD at the Oncology Department of Treichville University Hospital in Abidjan. We compared the differences between the programmed duration of chemotherapy and the actual duration of administration according to the two routes of administration.
View complete article: PDF  |  Full-text

Advances in the Treatment of Breast Cancer-Emphasis on fertility preservationA Case Report

With the recent advances in breast cancer treatment the 5 year survival rates have increased significantly with overall 20yrs survival in developed countries like USA. With further improvement being designed in the treatment of breast cancers with more and more sophisticated models to study breast cancer in human beings using the modern microfluidic models one expects more and younger breast cancer survivors to be needing fertility treatments. Here we review the modern advances in breast cancer treatments and the need for emphasizing on fertility preservation before starting any chemotherapeutic or other management as recommended by both ASO and ASRM.
View complete article: PDF  |  Full-text

Phase II Trial of Lower Dose Bevacizumab and Irinotecan in Relapsed High Grade Gliomas

Relapsed high-grade gliomas (HGG) respond poorly to known chemotherapeutic agents with a median survival of 3 to 6 months. Several phase II trials of Bevacizumab for salvage therapy, reported excellent response rates. The optimal dose of Bevacizumab in GBM has not been defined to date. We performed a prospective phase II trial of bevacizumab using 5 mg/kg every 2 weeks.
View complete article: PDF  |  Full-text


Submit Manuscript